Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
23.08. | Hedge Fund and Insider Trading News: Boaz Weinstein, Bill Ackman, Third Point, AQR Capital Management, Inhibrx Biosciences Inc (INBX), Comstock Resources Inc (CRK), and More | 3 | Insider Monkey | ||
14.08. | Inhibrx Biosciences, Inc. GAAP EPS of $125.40, revenue of $100M | 1 | Seeking Alpha | ||
14.08. | Inhibrx Biosciences, Inc.: Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights | 154 | PR Newswire | SAN DIEGO, Aug. 13, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials... ► Artikel lesen | |
17.06. | Inhibrx Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
11.06. | Inhibrx Biosciences files to sell 2.45M shares of common stock for holders | 1 | Seeking Alpha | ||
11.06. | Inhibrx Biosciences, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
24.05. | Inhibrx Biosciences, Inc. - 8-K, Current Report | 3 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 39,955 | -0,73 % | DAX-Check LIVE: Airbus, CTS Eventim, Deutsche Bank, DHL Group, Evotec, Qiagen, Volkswagen im Fokus | Der DAX ist mit leichten Zugewinnen in den neuen Monat gestartet. Gestern legte der deutsche Leitindex um 0,13 Prozent zu. Die Wall Street blieb feiertagsbedingt geschlossen. Worauf es jetzt für den... ► Artikel lesen | |
EVOTEC | 5,940 | -2,14 % | Erholungspotenzial: Nicht Evotec: 1 Biotech-Aktie mit Turnaround-Potenzial | © Foto: Silas Stein/dpaWährend die Aktien des Auftragsforschungsunternehmens Evotec noch fallen, hat dieser Biotechwert bereits die Wende vollzogen. Impfstoffe haben dazu beigetragen, dass viele Krankheiten... ► Artikel lesen | |
DYNE THERAPEUTICS | 33,040 | -1,81 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
NUVALENT | 86,25 | +1,52 % | Nuvalent stock retains Overweight rating as Barclays focuses on Phase 1 ROS1 data at ESMO | ||
BIONTECH | 81,45 | +0,37 % | BioNTech Aktie: Neue Daten auf ESMO-Kongress | ||
IMMUNOVANT | 34,030 | +1,22 % | Immunovant Inc.: Immunovant to Host Graves' Disease Program Update on September 9, 2024 | ||
TARSUS PHARMACEUTICALS | 30,650 | +12,23 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements | Generated $24.7 million in net product sales of XDEMVY®, an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients Secured multiple commercial payer contracts... ► Artikel lesen | |
ADMA BIOLOGICS | 16,250 | -3,04 % | Adma biologics executive trades shares worth over $400,000 | ||
BAVARIAN NORDIC | 31,410 | -0,25 % | AKTIONÄR-Depotwert Bavarian Nordic: UNICEF mit Paukenschlag | Die Ausbreitung von Mpox in Afrika bereitet Experten weiterhin Sorgen. Um das Problem in den Griff zu bekommen, hat das UN-Kinderhilfswerk UNICEF in mehreren Ländern eine Notfallausschreibung für Mpox-Impfstoff... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 12,290 | -1,68 % | Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024 | MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,915 | -4,13 % | Recursion Pharmaceuticals, Inc.: Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability | REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment... ► Artikel lesen | |
CG ONCOLOGY | 38,020 | +1,22 % | CG Oncology director sells over $23 million in company stock | ||
BB BIOTECH | 39,100 | -2,62 % | BB Biotech: Vom neuen Sektor-Aufschwung profitieren | Die Anzeichen einer neuen Biotech-Hausse verdichten sich. Immer mehr Profis positionieren sich für eine längerfristige Sektor-Rallye. Cleveres Stockpicking ist jetzt entscheidend. Alternativ setzen... ► Artikel lesen | |
ARCELLX | 71,20 | +1,18 % | Arcellx CMO sells over $239k in company stock | ||
JANUX THERAPEUTICS | 41,330 | -5,44 % | Navigating 5 Analyst Ratings For Janux Therapeutics |